KRM Ayurveda Limited, incorporated in 2019, operates in the Ayurvedic healthcare and wellness space. The company runs a network of Ayurvedic hospitals and clinics offering treatments, consultancy, and wellness solutions. It earns revenue through in-patient and out-patient services, Panchakarma therapies, sale of Ayurvedic medicines, wellness packages, and teleconsultation services. The company focuses on chronic lifestyle and metabolic disorders using classical Ayurvedic formulations and personalized care.

The Company is led by Promoter, i.e.,MR. PUNEET DHAWAN AND MRS. TANYA DHAWAN

The Revenues from operations for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 4,865.43 Lakh, ₹ 7,694.97 Lakh, ₹ 6,757.17 Lakh, and ₹ 8,937.59 Lakh, The EBITDA for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 1,283.41 Lakh, ₹ 1,910.90 Lakh, ₹ 733.66 Lakh, and ₹ 1,102.82 Lakh, The Profit after Tax for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 813.92 Lakh, ₹ 1,209.72 Lakh, ₹ 341.22 Lakh, and ₹ 759.80 Lakh, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue  EPS of ₹ 8.06 and post-issue EPS of ₹ 5.69 for FY25. The pre-issue P/E ratio is 16.75x,while the post-issue P/E ratio is 23.73x against the Industry P/E ratio is 43.52x The company's ROE for FY25 is 67.86% and RoNW is 67.86% The Annualised EPS is ₹ 7.66x and P/E is 17.63x, These metrics suggest that the IPO is Fully priced.

 
The Grey Market Premium (GMP) of KRM Ayurveda showing listing gains of 0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the KRM Ayurveda Limited. IPO for Listing gain or Long Term Purposes.